Compare FRT & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRT | RDY |
|---|---|---|
| Founded | 1962 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 9.9B |
| IPO Year | 1994 | 2001 |
| Metric | FRT | RDY |
|---|---|---|
| Price | $113.81 | $11.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $112.08 | $16.90 |
| AVG Volume (30 Days) | 591.7K | ★ 2.2M |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.09% | 0.52% |
| EPS Growth | ★ 36.84 | N/A |
| EPS | ★ 1.81 | N/A |
| Revenue | ★ $1,278,975,000.00 | N/A |
| Revenue This Year | $6.10 | $7.72 |
| Revenue Next Year | $4.64 | $3.50 |
| P/E Ratio | $62.94 | ★ $18.67 |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $90.03 | $11.36 |
| 52 Week High | $128.21 | $15.67 |
| Indicator | FRT | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 31.42 |
| Support Level | $112.67 | $11.36 |
| Resistance Level | $119.41 | $13.90 |
| Average True Range (ATR) | 1.49 | 0.17 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 9.23 | 4.88 |
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 103 properties, which includes 28.8 million square feet of retail space and 2,500 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.